New HIV pill CL-197 shows promise in early trial for untreated patients
NCT ID NCT07308782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing an experimental drug called CL-197 in 24 adults with HIV-1 who have never taken any anti-HIV drugs. The goal is to see if a single dose can lower the amount of virus in the blood and to check for side effects. Participants will be monitored for about two weeks. This is an early-phase study, so it focuses on safety and how the drug works, not on a long-term cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Youan Hospital, Capital Medical University
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo